Abstract
This chapter describes the preparations of coupling methods of antibodies and ligands for targeted drug conjugates and for targeted drug liposomes. To prepare antibody-mediated targeting drug (referring to as antibody-drug conjugate, ADC), or antibody-mediated targeting drug liposomes, there are many approaches of coupling methods. According to the types of coupling agents, the methods usually consist of homobifunctional and heterobifunctional cross-linking approaches. To prepare ligand-mediated targeting drug or ligand-mediated targeting drug liposomes, various chemical modification and synthesis method can be used, depending on the clinical treatment purposes and material structures. The following will describe the typical protocol examples for preparing the targeted drug conjugates and targeted drug liposomes.
References
Apelgren LD, Bailey DL (1993) Chemo immunoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid- monoclonal antibody constructs. Bioconjug Chem 4(2):121–126
Apelgren LD, Zimmerman DL (1990) Antitumor activity of the monoclonal antibody-vinca alkaloid immuno conjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer. Cancer Res 50(12):3540–3544
Chabner A, Roberts TG (2005) Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 5(1):65–72
Chari RVJ (1998) Targeted delivery of chemotherapeutics: tumor activated prodrug therapy. Adv Drug Deliv Rev 31(1–2):89–104
Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41(1):98–107
Chari RVJ, Jackel KA (1995) Enhancement of the selectivity and antitumor efficacy of a CC-1065 analog through immunoconjugate formation. Cancer Res 55(18):4079–4084
Dubowchik GM, Walker MA (1999) Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther 83(2):67–123
Hamann PR, Hinman LM (2002a) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia: choice of linker. Bioconjug Chem 13(1):40–46
Hamann PR, Hinman LM (2002b) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody- alicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13(1):47–58
Hamblett KJ, Senter PD (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10(20):7063–7070
Hartley JA (2011) The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs 20:733–744
Hinman LM, Hamann PR (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 53(14):3336–3342
Hughes B (2010) Antibody-drug conjugates for cancer: poised to deliver? Nat Rev Drug Discov 9(9):665–667
Jaracz S, Chen J (2005) Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 13(17):5043–5054
Laguzza BC, Nichols CL (1989) New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and pepresentative in vivo activity. J Med Chem 32(3):548–555
Lee CC, Gillies ER (2006) A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 coloncarcinomas. Proc Natl Acad Sci 103(45):16649–16654
Liu CN, Tadayoni BM (1996) Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A 93(16):8618–8623
Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M (1995) Target ability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta 1234(1):74
Monkovic I, Knipe JO (1991) New hydrazone derivatives of adriamycin and their immunoconjugates- a correlation between acid stability and cytotoxicity. Bioconjug Chem 2(3):133–141
Ojima I, Geng XD (2002) Tumor-specific noveltaxoid-monoclonal antibody conjugates. J Med Chem 45(2012):5620–5623
Parakh S, Parslow AC (2015) Antibody-mediated delivery of therapeutics for cancer therapy. Expert Opin Drug Deliv 13(3):401–419
Patel VF, Hardin JN (1995) Novel trityl linked drug immunoconjugates for cancer therapy. Bioorg Med Chem Lett 5(5):507–512
Peters C, Brown S (2015) Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep 35(4):e00225
Rameshwar P, Jose PA (2012) Cellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano ehicle based on poly(β-L-malic acid). Int J Mol Sci 13(2012):11681–11693
Russell J, Sanderson MA (2004) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immune conjugate. Clin Caner Res 11(2005):843–852
Sanderson RJ, Hering MA (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 11(2Pt1):843–852
Scott AM, Wolchok JD (2012) Antibody therapy of cancer. Nat Rev Cancer 12(2012):278–287
Sergii K, Chloe M (2017) Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates. Eur J Med Chem 142(2017):376–382
Shefet-Carasso L, Benhar I (2015) Antibody-targeted drugs and drug resistance-challenges and solutions. Drug Resist Updat 18(2014):36–46
Shen WC, Ryser HJ (1981) Cis-aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem Bioph Res Commun 102(3):1048–1054
Srinivasachar K, Neville DM (1989) New protein cross-linking reagents that are cleaved by mild acid. Biochemistry 28(6):2501–2509
Sutherland MSK, Walter RB (2013) SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122:1455–1463
Szakacs G, Paterson JK (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219–234
Teicher BA, Chari RV (2011) Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 17(20):6389–6397
Ulbrich K, Etrych T (2003) HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity. J Control Release 87(1–3):33–47
Ulbrich K, Etrych T (2004) Antibody-targeted polymer-doxorubicinconjugates with pH-controlled activation. J Drug Target 12(8):477–489
Yu Y, Wang Z-H, Zhang L, Yao H-J, Zhang Y, Li R-J, Ju R-J, Wang X-X, Zhou J, Li N, Lu W-L (2012) Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomaterials 33(6):1808–1820
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Germany, part of Springer Nature
About this entry
Cite this entry
Chen, M., Ma, QR., Lu, WL. (2019). Coupling Methods of Antibodies and Ligands for Liposomes. In: Lu, WL., Qi, XR. (eds) Liposome-Based Drug Delivery Systems. Biomaterial Engineering. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49231-4_22-1
Download citation
DOI: https://doi.org/10.1007/978-3-662-49231-4_22-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-49231-4
Online ISBN: 978-3-662-49231-4
eBook Packages: Springer Reference Chemistry and Mat. ScienceReference Module Physical and Materials ScienceReference Module Chemistry, Materials and Physics